[go: up one dir, main page]

HUP0101608A2 - Pharmaceutical aerosol formulation and process for its preparation - Google Patents

Pharmaceutical aerosol formulation and process for its preparation

Info

Publication number
HUP0101608A2
HUP0101608A2 HU0101608A HUP0101608A HUP0101608A2 HU P0101608 A2 HUP0101608 A2 HU P0101608A2 HU 0101608 A HU0101608 A HU 0101608A HU P0101608 A HUP0101608 A HU P0101608A HU P0101608 A2 HUP0101608 A2 HU P0101608A2
Authority
HU
Hungary
Prior art keywords
preparation
aerosol
aerosol formulation
pharmaceutical aerosol
namely
Prior art date
Application number
HU0101608A
Other languages
Hungarian (hu)
Inventor
Pascal Cavaillon
Nathalie Llorca
Olivier Louis
Patrick Rosier
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808152.4A external-priority patent/GB9808152D0/en
Priority claimed from GBGB9814709.3A external-priority patent/GB9814709D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HUP0101608A2 publication Critical patent/HUP0101608A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány az alábbiakat tartalmazó aeroszol formájúgyógyszerkészítményre vonatkozik: A) legalább egy bevonó kötőanyaggal,mégpedig laktózzal vagy trehalózzal és legalább egy felületaktívanyaggal bevont részecske formájú terápiás szer, és b) egycseppfolyósított hajtógáz, mégpedig 1,1,1,2-tetrafluor-etán,1,1,1,2,3,3,3-heptafluor-propán vagy ezek keveréke. A találmánykiterjed a fenti aeroszol formájú gyógyszerkészítmények előállítására,az ezekben lévő részecskékre és az aeroszol formájúgyógyszerkészítményt tartalmazó patronokra is. A készítmények légútibetegségek kezelésére alkalmasak. ÓThe invention relates to a medicinal preparation in the form of an aerosol containing the following: A) a therapeutic agent in particle form coated with at least one coating binder, namely lactose or trehalose and at least one surfactant, and b) a mono-liquefied propellant gas, namely 1,1,1,2-tetrafluoroethane,1 ,1,1,2,3,3,3-heptafluoropropane or a mixture thereof. The invention extends to the production of the above-mentioned pharmaceutical preparations in aerosol form, to the particles contained in them and also to the cartridges containing the pharmaceutical preparation in aerosol form. The preparations are suitable for the treatment of respiratory diseases. HE

HU0101608A 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation and process for its preparation HUP0101608A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808152.4A GB9808152D0 (en) 1998-04-18 1998-04-18 Pharmaceutical aerosol formulation
GBGB9814709.3A GB9814709D0 (en) 1998-07-08 1998-07-08 Pharmaceutical aerosol formulation
PCT/EP1999/002535 WO1999053901A1 (en) 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
HUP0101608A2 true HUP0101608A2 (en) 2002-03-28

Family

ID=26313483

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101608A HUP0101608A2 (en) 1998-04-18 1999-04-15 Pharmaceutical aerosol formulation and process for its preparation

Country Status (30)

Country Link
US (1) US7521042B2 (en)
EP (1) EP1073417B1 (en)
JP (1) JP2002512183A (en)
KR (1) KR20010042816A (en)
CN (1) CN1145478C (en)
AP (1) AP2000001961A0 (en)
AR (1) AR018183A1 (en)
AT (1) ATE228823T1 (en)
AU (1) AU755066B2 (en)
BR (1) BR9909736A (en)
CA (1) CA2328882A1 (en)
CO (1) CO5021210A1 (en)
DE (1) DE69904312T2 (en)
DK (1) DK1073417T3 (en)
EA (1) EA200000956A1 (en)
EE (1) EE200000608A (en)
ES (1) ES2189410T3 (en)
HR (1) HRP20000689A2 (en)
HU (1) HUP0101608A2 (en)
ID (1) ID27887A (en)
IL (1) IL139087A0 (en)
IS (1) IS5665A (en)
MA (1) MA26621A1 (en)
NO (1) NO20005218L (en)
NZ (1) NZ507619A (en)
PE (1) PE20000433A1 (en)
PL (1) PL343491A1 (en)
PT (1) PT1073417E (en)
TR (1) TR200100144T2 (en)
WO (1) WO1999053901A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
PT1169019E (en) 1999-04-14 2003-07-31 Glaxo Group Ltd PHARMACEUTICAL FORMULA IN AEROSOL
DE60132239T2 (en) † 2000-11-30 2008-05-08 Vectura Ltd., Claverton Down METHOD FOR PREPARING MICROPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS FOR INHALATION
ES2708961T3 (en) 2000-11-30 2019-04-12 Vectura Ltd Pharmaceutical compositions for inhalation
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
JP4680601B2 (en) * 2002-12-17 2011-05-11 メディミューン・エルエルシー High pressure spray drying of bioactive materials
ITMI20022674A1 (en) * 2002-12-18 2004-06-19 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF STERILE FORMULATIONS BASED ON MICRONIZED CRYSTALLINE PHARMACEUTICAL ACTIVE SUBSTANCES TO BE ADMINISTERED AS WATER SUSPENSION BY INHALATION.
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
WO2004103348A2 (en) * 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
CN101155590A (en) * 2005-02-10 2008-04-02 葛兰素集团有限公司 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8236862B2 (en) 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
EP4403231A3 (en) 2009-02-26 2024-10-23 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
BR112012000890A2 (en) 2009-07-15 2017-10-31 Theravance Inc crystalline free base forms of a biphenyl compound
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CN104744215B (en) 2010-03-03 2019-03-15 尼昂克技术公司 Pharmaceutical compositions containing monoterpenes
HUE035763T2 (en) 2010-06-08 2018-05-28 Kobe Gakuin Educational Found Coated particle and method for producing coated particle
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
US9211269B2 (en) 2010-12-17 2015-12-15 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
CN102366405A (en) * 2011-10-21 2012-03-07 江阴长风医药科技有限公司 Fluticasone propionate aerosol preparation with hydrofluoroalkane as propellant
KR20150041608A (en) 2012-02-28 2015-04-16 아이슈티카 홀딩스 인코포레이티드. Inhalable pharmaceutical compositions
WO2014140647A1 (en) 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
EP3231444B1 (en) 2014-05-12 2019-12-18 Verona Pharma PLC New treatment
EP3872069A1 (en) 2015-02-12 2021-09-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN106546751A (en) * 2016-11-16 2017-03-29 广州华弘生物科技有限公司 For detecting the enzyme linked immunological kit of OCT4 albumen
JP7144411B2 (en) 2016-11-30 2022-09-29 ネオンク テクノロジーズ インク． Perillyl alcohol-3-bromopyruvate conjugate and cancer treatment method
DK3749291T3 (en) 2018-02-08 2024-04-08 Univ Southern California METHODS OF PERMEABILIZING THE BLOOD-BRAIN BARRIER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
ES2053549T3 (en) * 1986-08-11 1994-08-01 Innovata Biomed Ltd A PROCESS FOR THE PREPARATION OF AN APPROPRIATE PHARMACEUTICAL FORMULATION FOR INHALATION.
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0655237A1 (en) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medicinal aerosol formulation
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
ES2191101T3 (en) * 1995-06-12 2003-09-01 Ono Pharmaceutical Co GRANULES CONTAINING PRANLUKAST, PROCEDURE FOR THE PRODUCTION OF GRANULES AND PROCEDURE FOR REDUCING THE COHESION OF PRANLUKAST.
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
EP0951300A4 (en) * 1996-12-31 2006-07-26 Nektar Therapeutics Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes

Also Published As

Publication number Publication date
ES2189410T3 (en) 2003-07-01
CA2328882A1 (en) 1999-10-28
PT1073417E (en) 2003-04-30
TR200100144T2 (en) 2001-06-21
US7521042B2 (en) 2009-04-21
PL343491A1 (en) 2001-08-27
AP2000001961A0 (en) 2000-12-31
NZ507619A (en) 2003-05-30
NO20005218L (en) 2000-11-10
AR018183A1 (en) 2001-10-31
DK1073417T3 (en) 2003-03-24
ID27887A (en) 2001-05-03
BR9909736A (en) 2000-12-19
DE69904312D1 (en) 2003-01-16
PE20000433A1 (en) 2000-05-26
MA26621A1 (en) 2004-12-20
EP1073417B1 (en) 2002-12-04
KR20010042816A (en) 2001-05-25
AU755066B2 (en) 2002-12-05
AU3523199A (en) 1999-11-08
JP2002512183A (en) 2002-04-23
CN1305369A (en) 2001-07-25
EA200000956A1 (en) 2001-04-23
NO20005218D0 (en) 2000-10-17
WO1999053901A1 (en) 1999-10-28
EE200000608A (en) 2001-08-15
CN1145478C (en) 2004-04-14
CO5021210A1 (en) 2001-03-27
ATE228823T1 (en) 2002-12-15
IL139087A0 (en) 2001-11-25
HRP20000689A2 (en) 2001-02-28
DE69904312T2 (en) 2003-10-16
EP1073417A1 (en) 2001-02-07
IS5665A (en) 2000-10-13
US20030157032A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
HUP0101608A2 (en) Pharmaceutical aerosol formulation and process for its preparation
AU4260496A (en) Propellant mixture for aerosol formulation
HUP0000714A2 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
UA42047C2 (en) Pharmaceutical aerosol preparation, method for its manufacture, and method of treatment using this preparation
HUP9802391A2 (en) Inhaler device for administering salmeterol in measured doses
BR9712125A (en) Pharmaceutical formulation in aerosol, use of a mixture, pharmaceutical product, and process of administration of budesonide to a patient
MY115688A (en) Pharmaceutical composition for administration by inhalation
HUP0102892A2 (en) Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use
IL143293A0 (en) Pharmaceutical aerosol composition containing hfa 227 and hfa 134a
IT1255040B (en) FORM OF CYCLOSPORINE SUITABLE FOR PULMONARY TRACT ADMINISTRATION AND PREPARATION PROCEDURE.
GR3037044T3 (en) Non-chlorofluorocarbon aerosol formulations.
EA200100338A1 (en) METHOD AND DEVICE FOR INTRODUCTION OF EXISTING SUBSTANCE IN THE FORM OF AEROSOL IN LUNG PATIENT
DE60321774D1 (en) AEROSOL FORMULATIONS OF FORMOTEROL AND MOMETASON
SE0002643L (en) Inhalation preparations containing microparticles
GR3018168T3 (en) Medicaments.
GB2332372B (en) Pharmaceutical aerosol compositions
AU4417500A (en) Pharmaceutical aerosol formulation
HUP0000841A2 (en) New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising budesonide and process for its preparation
HUP0000843A2 (en) New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising formoterol
NO980858D0 (en) Pharmaceutical preparations and devices for administration thereof
HUP0003207A2 (en) Proliposome powders for inhalation stabilised by tocopherol, pharmaceutical compositions containing the same and the use of them
HK1048064A1 (en) Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
HUP0000755A2 (en) New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
HUP0002533A2 (en) New combination of antiasthma medicaments
TH59260A3 (en) Dosing of the active ingredient that has been aerosolized